Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)

NCT02779101 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Primary Central Nervous System Lymphoma

Interventions

DRUG: pembrolizumab

Sponsor

Prof. Dr. Matthias Preusser